AU2022378576A1 - Endoxifen for treatment of cancers - Google Patents

Endoxifen for treatment of cancers Download PDF

Info

Publication number
AU2022378576A1
AU2022378576A1 AU2022378576A AU2022378576A AU2022378576A1 AU 2022378576 A1 AU2022378576 A1 AU 2022378576A1 AU 2022378576 A AU2022378576 A AU 2022378576A AU 2022378576 A AU2022378576 A AU 2022378576A AU 2022378576 A1 AU2022378576 A1 AU 2022378576A1
Authority
AU
Australia
Prior art keywords
endoxifen
cancer
subject
response
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022378576A
Other languages
English (en)
Inventor
Carla Grandori
Katannya KAPELI
Steven C. Quay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atossa Therapeutics Inc
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of AU2022378576A1 publication Critical patent/AU2022378576A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022378576A 2021-10-28 2022-10-27 Endoxifen for treatment of cancers Pending AU2022378576A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272869P 2021-10-28 2021-10-28
US63/272,869 2021-10-28
PCT/US2022/048061 WO2023076496A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Publications (1)

Publication Number Publication Date
AU2022378576A1 true AU2022378576A1 (en) 2024-03-28

Family

ID=86158538

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022378576A Pending AU2022378576A1 (en) 2021-10-28 2022-10-27 Endoxifen for treatment of cancers

Country Status (10)

Country Link
US (1) US20250041245A1 (https=)
EP (1) EP4422608A4 (https=)
JP (1) JP2024541900A (https=)
KR (1) KR20240093500A (https=)
CN (1) CN118159259A (https=)
AU (1) AU2022378576A1 (https=)
CA (1) CA3232972A1 (https=)
IL (1) IL312037A (https=)
MX (1) MX2024005220A (https=)
WO (1) WO2023076496A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304574A4 (en) * 2021-03-11 2024-11-20 Atossa Therapeutics, Inc. ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER
CN117338780A (zh) * 2023-09-21 2024-01-05 中国人民解放军海军军医大学 帕罗西汀在制备抗肿瘤药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013033430A1 (en) * 2011-09-02 2013-03-07 Wake Forest School Of Medicine Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
ES2769634T3 (es) * 2011-11-04 2020-06-26 Szewczuk Myron R Uso de inhibidores de la sialidasa NEU1 en el tratamiento del cáncer
DE102015222031A1 (de) * 2015-11-10 2017-05-11 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Synthese von (Z)-Endoxifenhydrochlorid
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
JP7792335B2 (ja) * 2019-12-12 2025-12-25 センティ バイオサイエンシズ インコーポレイテッド 細胞の調節されたアーマリングのための方法及び組成物
EP4304574A4 (en) * 2021-03-11 2024-11-20 Atossa Therapeutics, Inc. ENDOXIFEN FOR THE TREATMENT OF OVARIAN CANCER
AU2023260712A1 (en) * 2022-04-26 2024-11-14 Atossa Therapeutics, Inc. High dose endoxifen formulations and methods of use

Also Published As

Publication number Publication date
EP4422608A4 (en) 2025-09-24
WO2023076496A1 (en) 2023-05-04
IL312037A (en) 2024-06-01
JP2024541900A (ja) 2024-11-13
CA3232972A1 (en) 2023-05-04
CN118159259A (zh) 2024-06-07
EP4422608A1 (en) 2024-09-04
MX2024005220A (es) 2024-05-16
US20250041245A1 (en) 2025-02-06
KR20240093500A (ko) 2024-06-24

Similar Documents

Publication Publication Date Title
US12281056B2 (en) Methods for making and using endoxifen
US20250041245A1 (en) Endoxifen for treatment of cancers
TW202340135A (zh) （ｚ）—因多昔芬之組合物及其富集方法
WO2022192488A1 (en) Endoxifen for treatment of ovarian cancer
WO2024091551A1 (en) Crystalline forms, pharmaceutical compositions and methods of use thereof
HK40105626A (zh) 用於治疗癌症的因多昔芬
WO2025151443A1 (en) Endoxifen for treatment of rare cancers
CN121568688A (zh) 因多昔芬组合物及其使用方法及其合成
HK40031003A (en) Methods for making and using endoxifen